UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 129

Sortiert nach

Immunotherapy and brain metastasis in lung cancer: connecting bench side science to the clinic

Frontiers in immunology, 2023-10, Vol.14, p.1221097-1221097

2023

Link zum Volltext

Verfügbarkeit prüfen

Acquired Mechanisms of Resistance to Osimertinib-The Next Challenge

Cancers, 2022-04, Vol.14 (8), p.1931

2022

Link zum Volltext

Verfügbarkeit prüfen

Targeting oncogenic ALK: a promising strategy for cancer treatment

Molecular cancer therapeutics, 2011-04, Vol.10 (4), p.569-579

2011

Link zum Volltext

Verfügbarkeit prüfen

Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples

Clinical lung cancer, 2017-11, Vol.18 (6), p.682-691.e5

2017

Link zum Volltext

Verfügbarkeit prüfen

Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study

Supportive care in cancer, 2021-01, Vol.29 (1), p.117-125

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer

Future oncology (London, England), 2021-03, Vol.17 (7), p.763-773

2021

Link zum Volltext

Verfügbarkeit prüfen

CD274 (PDL1) and JAK2 genomic amplifications in pulmonary squamous‐cell and adenocarcinoma patients

Histopathology, 2018-01, Vol.72 (2), p.259-269

2018

Link zum Volltext

Verfügbarkeit prüfen

Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control

Oncoimmunology, 2015-10, Vol.4 (10), p.e1040218-e1040218

2015

Link zum Volltext

Verfügbarkeit prüfen

CD33 Expression on Peripheral Blood Monocytes Predicts Efficacy of Anti-PD-1 Immunotherapy Against Non-Small Cell Lung Cancer

Frontiers in immunology, 2022-04, Vol.13, p.842653-842653

2022

Link zum Volltext

Verfügbarkeit prüfen

Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer

Journal of thoracic oncology, 2011-01, Vol.6 (1), p.21-27

2011

Link zum Volltext

Verfügbarkeit prüfen

Management of crizotinib therapy for ALK -rearranged non-small cell lung carcinoma: An expert consensus

Lung cancer (Amsterdam, Netherlands), 2015-02, Vol.87 (2), p.89-95

2015

Link zum Volltext

Verfügbarkeit prüfen

Comprehensive NGS profiling to enable detection of ALK gene rearrangements and MET amplifications in non-small cell lung cancer

Frontiers in oncology, 2023-10, Vol.13, p.1225646-1225646

2023

Link zum Volltext

Verfügbarkeit prüfen

MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside

Cancers, 2019-09, Vol.11 (10), p.1404

2019

Link zum Volltext

Verfügbarkeit prüfen

Diffuse dermal mucinosis secondary to colony‐stimulating factor 1 receptor monoclonal antibody treatment: A novel and peculiar drug‐induced diffuse cutaneous mucinosis

Journal of dermatology, 2021-03, Vol.48 (3), p.380-384

2021

Link zum Volltext

Verfügbarkeit prüfen

Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines

Laboratory investigation, 2008-05, Vol.88 (5), p.491-503

2008

Link zum Volltext

Verfügbarkeit prüfen

Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer

Breast cancer research and treatment, 2007-12, Vol.106 (2), p.181-189

2007

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Value of Clinical Staging According to TNM in Patients With SCLC: A Real-World Surveillance Epidemiology and End-Results Database Analysis

JTO clinical and research reports, 2022-01, Vol.3 (1), p.100266-100266, Article 100266

2022

Link zum Volltext

Verfügbarkeit prüfen

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain

BMC cancer, 2018-01, Vol.18 (1), p.106-106, Article 106

2018

Link zum Volltext

Verfügbarkeit prüfen

MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC)

Oncotarget, 2015-06, Vol.6 (18), p.16215-16226

2015

Link zum Volltext

Verfügbarkeit prüfen

RET Fusion Testing in Patients With NSCLC: The RETING Study

JTO clinical and research reports, 2024-04, Vol.5 (4), p.100653-100653, Article 100653

2024

Link zum Volltext

Verfügbarkeit prüfen

Multiple Brain Pseudoprogression in a Patient With NSCLC Treated With Pembrolizumab

JTO clinical and research reports, 2020-09, Vol.1 (3), p.100070, Article 100070

2020

Link zum Volltext

Verfügbarkeit prüfen

PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis

Journal of clinical medicine, 2021-10, Vol.10 (19), p.4583

2021

Link zum Volltext

Verfügbarkeit prüfen

Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel

Future oncology (London, England), 2015-01, Vol.11 (2), p.267-277

2015

Link zum Volltext

Verfügbarkeit prüfen

EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma

Journal of clinical medicine, 2019-04, Vol.8 (4), p.529

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 129

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(110)
Mit Volltextzugriff
(124)

Publikationsform

Artikel
(120)
Berichte
(9)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(77)
Life Sciences & Biomedicine
(76)
Oncology
(57)
Humans
(55)
Male
(31)
Female
(27)
Respiratory System
(26)
Lung Neoplasms - Pathology
(25)
Middle Aged
(23)
Aged
(22)
Lung Neoplasms - Genetics
(21)
Lung Neoplasms - Drug Therapy
(17)
Carcinoma, Non-Small-Cell Lung - Genetics
(14)
Lung Cancer
(14)
Adult
(13)
Carcinoma, Non-Small-Cell Lung - Pathology
(13)
Immunotherapy
(13)
Prognosis
(13)
Treatment Outcome
(13)
Chemotherapy
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Immunotherapy and brain metastasis in lung cancer: connecting bench side science to the clinic

Acquired Mechanisms of Resistance to Osimertinib-The Next Challenge

Targeting oncogenic ALK: a promising strategy for cancer treatment

Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples

Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study

Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer

CD274 (PDL1) and JAK2 genomic amplifications in pulmonary squamous‐cell and adenocarcinoma patients

Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control

CD33 Expression on Peripheral Blood Monocytes Predicts Efficacy of Anti-PD-1 Immunotherapy Against Non-Small Cell Lung Cancer

Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer

Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry

Management of crizotinib therapy for ALK -rearranged non-small cell lung carcinoma: An expert consensus

Comprehensive NGS profiling to enable detection of ALK gene rearrangements and MET amplifications in non-small cell lung cancer

MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside

Diffuse dermal mucinosis secondary to colony‐stimulating factor 1 receptor monoclonal antibody treatment: A novel and peculiar drug‐induced diffuse cutaneous mucinosis

Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines

Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer

Prognostic Value of Clinical Staging According to TNM in Patients With SCLC: A Real-World Surveillance Epidemiology and End-Results Database Analysis

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain

MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC)

RET Fusion Testing in Patients With NSCLC: The RETING Study

Multiple Brain Pseudoprogression in a Patient With NSCLC Treated With Pembrolizumab

PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis

Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel

EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma

Suchergebnisse filtern